OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Neurology Neurosurgery and Psychiatry is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
#3080 A systematic review of extra-motor symptom evaluation in clinical trials for amyotrophic lateral sclerosis	110
133 Multiple sclerosis and the risk of infection: a consensus guideline	93
090 Frequency of migraine and the use of preventive medication in a UK primary care population	84
West is best – a strongman with numb feet	79
053 Brainshuttle AD: Investigating safety, tolerability, and PK/PD of RG6102 in prodromal/mild-to-moderate AD	77
117 Who is the culprit – the virus or the anti-virus?	76
102 Levodopa and melanoma what do clinicians think?	74
194 CANVAS-related sensory ganglionopathy without severe ataxia – the importance of muscle afferents in proprioception	72
134 Predictors of serum vitamin D level in multiple sclerosis	70
072 Fenfluramine directly inhibits cortical spreading depolarisation: a patho physiologic process linked to SUDEP	69
193 Unusual presentation of hereditary neuropathy with liability to pressure palsies (HNPP)	67
192 Tacrolimus-induced chronic inflammatory demyelinating polyradiculoneuropa- thy (CIDP): a case series	67
086 Long-term efficacy of fremanezumab in migraine patients with inadequate response to prior preventive medication classes	62
092 Brain amylin accumulation in Parkinson’s disease is not driven by type 2 diabetes mellitus	60
033 Extracranial-tumor cerebri	60
018 A retrospective analysis of shunts for idiopathic intracranial hypertension: a 10-year experience at St. George’s University Hospital	58
Parallel Session 1: Muscle, nerve and quality\| Wed 18 May, 1115 – 1230\|04 Project NeuroSafe: safety practice in neurology services	57
205 Relationship between thrombin generation and micro-embolic signals in moderate-severe asymptomatic and symptomatic carotid stenosis patients	57
109 Embedding patient voice in trial design: the EJS ACT-PD experience	55
Cryptic confusion	55
061 The long-term effects of anterior temporal lobe resection on memory encoding: A longitudinal fMRI study	54
122 A case of posterior reversible encephalopathy syndrome: a rheumatologic conundrum	54
Idiopathic intracranial hypertension: evaluation of births and fertility through the hospital episode statistic dataset 2002–2020	52
089 Re-admission rate for patients with headache in Southwest London – can this be addressed?	52
059 Cannabidiol in refractory adult epilepsies: broadening the Lennox-Gastaut phenotype?	52

084 Migraine and sociodemographic factors a review	51
139 Characterising DARC (Detecting Apoptosing Retinal Cells) spots in optic neuritis	51
079 Does the timing of IIH diagnosis in relation to pregnancy affect outcomes?	51
074 No valvular heart disease or pulmonary artery hypertension with fenfluramine for up to 3 years	50
160 Ophthalmological involvement in m.3243A>G-related mitochondrial disease	49
129 Multiple sclerosis relapse patterns in a population-based cohort	48
163 Immunosuppression guidelines ongoing implementation project	46
091 The East London Parkinson’s disease project – engaging a diverse population in research	46
Call for emergency action to limit global temperature increases, restore biodiversity and protect health	45
#3115 Systematic review into the effects of sleep disorders on the development of PTSD	45
175 A case series of anti-HMGCR immune mediated necrotizing myopathy: the West Midlands data	45
Long-term maintenance of mycophenolate mofetil in anti-NMDA receptor encephalitis (LEARN): a multicentre, open-label, blinded-endpoint, randomised controlled trial	43
Impact of fish consumption on disability progression in multiple sclerosis	43
#3113 Evaluating the PCL-C as a measure of trauma and PTSD symptoms in patients with functional neurological symptom disorder	43
Cavernomas: a randomised effectiveness (CARE) trial: treatment with versus without neurosurgery for symptomatic brain cavernoma	42
256 FIREFISH part 2: risdiplam efficacy and safety in type 1 SMA	41
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)	41